RLF-OD032 demonstrated bioequivalence to KUVAN® Powder Study results support planned 505(b)(2) NDA submission in early 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback